510(k) device
Osteopal® V
Heraeus Medical GmbH · Bone Cement (LOD, Class II) · First FDA decision Dec 5, 2024, newest Dec 5, 2024Hip osteoarthritisKnee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Osteopal V"
MAUDE reports
0
Brand "Osteopal V", since 2015
PubMed studies
7
Mentioning "Osteopal V"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Osteopal® V
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Lumbar Artificial Disc Replacement (LADR)National determinationOn the books150.10Updated Nov 4, 2026
- Transcatheter Tricuspid Valve Replacement (TTVR)National analysisReview closedCAG-00467NUpdated Sep 24, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Lumbar Artificial Disc Replacement (LADR)National analysisReview closedCAG-00292RUpdated Sep 18, 2026
- Lumbar Artificial Disc ReplacementNational analysisReview closedCAG-00292NUpdated Sep 18, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Osteopal V", any status and sponsor, newest update first.
No registered device study names "Osteopal V".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Osteopal V", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LOD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Osteopal V"[tiab]. The summary above synthesizes these.
- Translation of a spinal bone cement product from bench to bedside.
Feng F, Chen M, Wang X, et al. · Bioact Mater · 2022
- Percutaneous vertebroplasty with high- versus low-viscosity bone cement for osteoporotic vertebral compression fractures.
Miao F, Zeng X, Wang W, et al. · J Orthop Surg Res · 2020
- Mechanical characterisation of three percutaneous vertebroplasty biomaterials.
Gheduzzi S, Webb JJ, Miles AW · J Mater Sci Mater Med · 2006Comparative Study
- The effect of unsaturated fatty acid and triglyceride oil addition on the mechanical and antibacterial properties of acrylic bone cements.
Persson C, Robert E, Carlsson E, et al. · J Biomater Appl · 2015Research Support, Non-U.S. Gov't
- The effect of oligo(trimethylene carbonate) addition on the stiffness of acrylic bone cement.
Persson C, López A, Fathali H, et al. · Biomatter · 2016Research Support, Non-U.S. Gov't
- Creep and fatigue behavior of a novel 2-component paste-like formulation of acrylic bone cements.
Köster U, Jaeger R, Bardts M, et al. · J Mater Sci Mater Med · 2013Comparative Study, Evaluation Study
- A clinical comparative study on low versus medium viscosity polymethylmetacrylate bone cement in percutaneous vertebroplasty: viscosity associated with cement leakage.
Nieuwenhuijse MJ, Muijs SP, van Erkel AR, et al. · Spine (Phila Pa 1976) · 2010Comparative Study
Other devices of this type
Also filed under product code LOD.
- Norian Srs Bone CementSynthes (Usa) · PMA 2000
- Cemex System Genta Fast Bone CementExactech, Inc. · 510(k) 2004
- SPECTRUM GV Bone CementOsteoremedies, LLC · 510(k) 2025
- PALACOS R pro, PALACOS R+G pro, PALACOS MV+G proHeraeus Medical GmbH · 510(k) 2021
- Refobacin Bone Cement R (110034355)Biomet France · 510(k) 2026
- Bone Cement Genta, Bone Cement HV, Bone Cement LVTecres S.P.A. · 510(k) 2023
- Bone Cement-Normal ViscosityBiomecanica Industria E Comerciode Produtos Ortopedicos Ltda · 510(k) 2022
- OGM 1 Polymethylmethacrylate (PMMA) bone cementOrmed Grup Medikal Turizm Saglik Hizmetleri Sanayi VE · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.